We are a leading provider of affordable pharmaceuticals to the hospital market, which we sell primarily throughout North America. Initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, we reincorporated as Sagent Pharmaceuticals Inc., a Delaware corporation, in connection with our initial public offering, on April 26, 2011. With a primary focus on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, we offer our customers a broad range of products across anti-infective, oncology and critical care indications in a variety of presentations including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. We generally seek to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Our management team includes industry veterans who have served critical functions at other pharmaceutical companies or key customer groups and have long-standing relationships with customers, regulatory agencies, and suppliers. We have rapidly established a growing and diverse product portfolio and product pipeline as a result of our innovative business model. Our model combines an extensive network of international development, sourcing and manufacturing collaborations with our proven and experienced regulatory, quality assurance, business development, project management, and sales and marketing teams.
![Sagent Pharmaceuticals logo](https://files.capedge.com/S-1A/0001193125-11-089495/g122348g24c16.jpg)
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NHS Pharmaceuticals, Sagent Holding Co.
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
9 Sep 16
EFFECT
Notice of effectiveness
2 Sep 16
POS AM
Prospectus update (post-effective amendment)
30 Aug 16
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 16
25-NSE
Exchange delisting
29 Aug 16
8-K
Completion of Acquisition or Disposition of Assets
29 Aug 16
SC 14D9/A
Tender offer solicitation (amended)
29 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
29 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
24 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
22 Aug 16
Latest ownership filings
SC 13G/A
Sagent Pharmaceuticals, Inc.
14 Feb 17
SC 13G/A
Sagent Pharmaceuticals, Inc.
2 Sep 16
4
Change in insider ownership
1 Sep 16
4
Change in insider ownership
1 Sep 16
4
MICHAEL FEKETE
31 Aug 16
4
DONALD R BULLOCK
31 Aug 16
4
Jeffrey W. Greve
31 Aug 16
4
MICHAEL V. WARD
31 Aug 16
4
Anthony Krizman
31 Aug 16
4
ROBERT J FLANAGAN
31 Aug 16
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|